

INFORMAZIONI
PERSONALI

Chiara Agrati

 chiara.agrati@opbg.net – agrati74@gmail.com

Gender: F | Nationality: Italian

POSIZIONE
ATTUALE

Head of the Unit of Pathogen Specific Immunity, Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

h-index: 43PROFESSIONAL
EXPERIENCE AND
POSITIONS

-
- | | |
|---------------------|--|
| Sett 2022 – oggi | Head of the Unit of Pathogen Specific Immunity , Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù |
| Lug 2016 – Ago 2022 | Head of the Cellular Immunology and Pharmacology Laboratory
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory di Virologia, INMI “L. Spallanzani” |
| Gen 2008 – Lug 2016 | Biologist, Permanent staff
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory di Virologia, INMI “L. Spallanzani” |
| Apr 2007 – Dic 2007 | Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Cellular Immunology
Projects: Emerging infectious diseases; cytokine storm, set up diagnostic tests, influenza cross-immunity |
| Apr 2005 – Mar 2006 | Researcher
INMI “Lazzaro Spallanzani” - I.R.C.C.S. – Laboratory of Cellular Immunology
Projects: Cross talk between innate and adaptive cells during chronic infections; analysis of immune reconstitution in chronic HIV patients; gammadelta t cell immunity against emerging viruses (SARS-CoV and orthopoxviruses). |
| Apr 2004 – Giu 2004 | Researcher, temporary staff
INMI “Lazzaro Spallanzani” - I.R.C.C.S., Laboratory of Virology
Projects: SARS emergency; Support for SARS emergency diagnostics. Set up of immunological test to evaluate the antigen specific T cell response. |

- Gen 2004- Mar 2005 **Researcher**
INMI "Lazzaro Spallanzani" - I.R.C.C.S., Laboratory of Cellular Immunology
Project: Innate immune response during HCV infection
- Dic 2001 – Dic 2003 **Researcher**
INMI "Lazzaro Spallanzani" - I.R.C.C.S., Laboratory of Cellular Immunology
European Project: n.QLK2-CT-1999 entitled "TB vaccin cluster"
- Nov 1999 – Mar 2001 **Research fellowship**
INMI "Lazzaro Spallanzani" - I.R.C.C.S., Laboratory of Cellular Immunology
- Gen 1999 – Nov 1999 **Researcher**
INMI "Lazzaro Spallanzani" - I.R.C.C.S.
Project: International Centre for AIDS and Emerging & Re-emerging infections (ICAERI)
- Nov 1996 – Giu 1998 **Researcher**
Università degli studi di Roma "Sapienza"
Project: Muscarinic receptor characterization on neurons

EDUCATION, AND POSITION

Academic Education

- 2007 **PhD in Immunology**
University of Rome, "Tor Vergata"
- 2003 **Specialty degree in Medical Microbiology and Virology** – 50/50 e lode
University of Rome, "Tor Vergata"
- 1998 **Degree in Biology** – 110/110 e lode
University of Rome "La Sapienza"

Qualifying and/or Licensing Training

- 2019 **Sorting cellular: "MACS-Quant Tyto**
Colonia, Germany
- 2007 **Hand-on course for handling class 4 agents**
INMI L. Spallanzani – IRCCS
- 2007 **International High Containment Biosafety**
Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada

INCARICHI

- 2025-oggi **Member of the Executive Board of the Italian Society of Cytometry**

- 2024 **Appointment at the Italian Medicines Agency (AIFA)** for the procedure EMEA/H/C/006370 concerning the centralized marketing authorization application submitted to the European Medicines Agency (EMA) for a specific medicinal product within the European Union and the European Economic Area
- 2022-oggi **Member of the PhD Program Faculty Board** “Innovation in Immuno-mediated and hematological disorder” - University of Rome “Sapienza”
- 2022-oggi **Head of the “Pathogen-Specific Immunity” Research Unit** within the Department of Oncohematology, Cellular Therapies, Gene Therapies and Hematopoietic Transplantation at Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy.
- 2021-2022 **Member of the Annual Evaluation Committee** for Health Researchers and Professional Health Research Collaborators at the National Institute for Infectious Diseases “L. Spallanzani” (INMI), Rome, Italy
- 2019-2022 **Member of the Scientific and Technical Committee** of the National Institute for Infectious Diseases “L. Spallanzani” (INMI)
- 2016-2022 **Head of UOSD** “Cellular Immunology Laboratory” – INMI L Spallanzani

ABILITAZIONI SCIENTIFICHE

- 2022 **Italian National Scientific Qualification for Full Professorship** in Competition Sector 06/A2 – General Pathology and Clinical Pathology
- 2022 **Italian National Scientific Qualification for Associate Professorship** in Competition Sector 06/A2 – General Pathology and Clinical Pathology
- 2022 **Italian National Scientific Qualification for Associate Professorship** in Competition Sector 06/A3 – Microbiology and Clinical Microbiology

ATTIVITA’ DIDATTICA

PhD School

- 2022-oggi **Faculty Member of the PhD Program** in “Innovation in Immuno-Mediated and Hematological Disorders” at Sapienza University of Rome.

Docente in Master Universitari

- 2024 **Teaching appointment within the Second-Level Master’s Program in Molecular Virology**, University of Rome Tor Vergata – Academic Year 2023/2024.
“SARS-CoV-2 Pathogenesis”
“The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects”
- 2022 **Teaching appointment within the Second-Level Master’s Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2020/2021.

"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"

- 2021 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2020/2021.
"SARS-CoV-2 Pathogenesis"
"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"
- 2019 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2018/2019.
"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"
- 2018 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2017/2018.
"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"
- 2017 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2016/2017.
"HIV: conoscere per prevenire"
- 2016 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2015/2016.
"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"
"HIV: conoscere per prevenire"
- 2015 **Teaching appointment within the Second-Level Master's Program in Molecular Virology**, University of Rome Tor Vergata - A.A. 2014/2015.
"The New Ebola Virus Outbreak: Virological and Pathogenesis Aspects"

Seminari Scientifici presso Università

- 2024 **Lessons for Medicine students (Unicamillus University):** "Immune diagnosis and monitoring for M. Tuberculosis" (course led by Prof Di Caro).
- 2024 **Lessons for Medicine students (Unicamillus University):** "Immune response: from pathogenesis to immunotherapy" (course led by Prof Ippolito).

Attività di tutoraggio per tesi

- AA 2024-2025 **Co-supervisor of the Degree Thesis in Medicine and Surgery** of Alessandra Basile (UniCamillus University). Thesis title: "Letermovir Prophylaxis and Immune Response in Hematopoietic Stem Cell Transplant Recipients".
- AA 2024--2025 **Co-supervisor of the Specialization Thesis** in Microbiology and Virology of Claudia Pinacchio (Sapienza University of Rome). Thesis title: "Monitoring T-Cell Functionality in Patients Treated with CAR-CD7 Lymphocytes: Possible Implications for Antiviral Response".

PROFILO PROFESSIONALE

Dr. Chiara Agrati holds a PhD in Immunology and a Specialization degree in Microbiology and Virology. Her comprehensive training in immunology and virology has enabled her to rigorously investigate the complex mechanisms underlying host–pathogen interactions across different clinical settings.

Dr. Agrati has been conducting research at INMI since 1999, initially through research fellowships and contracts and, since 2008, as a Senior Biologist. Since 2006, she has participated in numerous research projects on emerging pathogens, contributing to the development of immunotherapeutic strategies and emergency response plans, progressively taking on coordination and high-specialization roles in the field of immunovirology.

In 2016, she was appointed Head of the Cellular Immunology Laboratory at the National Institute for Infectious Diseases “Lazzaro Spallanzani” in Rome, where she coordinated both diagnostic and research activities focused on the immune response to viral diseases. Her research activity is primarily focused on the analysis of protective and pathogenic mechanisms and on the definition of protective immune profiles. In the context of chronic infections, she characterized the impairment of $\gamma\delta$ T cells during HIV infection and identified the mechanisms underlying this immune dysfunction, also contributing to the definition of the potential of $\gamma\delta$ T cells as targets for HIV immunotherapy. She also identified a functional marker of CD4 T cells associated with ineffective immune recovery and described the key role of dendritic cell– $\gamma\delta$ T cell interactions in the development of protective immunity.

Dr. Agrati has also been actively involved in numerous projects on emerging viral infections. She identified $\gamma\delta$ T cells as key players in modulating the protective immune response against SARS-CoV and demonstrated their ability to eliminate cells infected by SARS-CoV, orthopoxviruses, and Zika virus. During the Ebola outbreak, she was part of a clinical and research task force, reporting a profound impairment of the adaptive T-cell response during the acute phase of Ebola infection, with consequent reactivation of herpesviruses. She also has extensive experience working in Biosafety Level 3 and 4 laboratories.

Since 2020, she has coordinated several projects on the immune response to COVID-19, aimed at identifying protective immune profiles, mechanisms of pathogenesis, and vaccine responses in both healthy and vulnerable populations. Her studies have demonstrated the central role of inflammation in severe forms of COVID-19, characterized by a reduction in the cytotoxic immune compartment and an expansion of suppressor cells capable of dampening the immune response and predicting fatal outcomes. She also led the immunological arm of a national multicenter study on vaccine immunogenicity in fragile populations.

In 2022, she moved to the Bambino Gesù Pediatric Hospital, where she heads the Pathogen-Specific Immunity Unit within the Department of Hematology and

Oncology. In recent years, her research has focused on identifying novel strategies to enhance antiviral immune responses in immunocompromised children and on defining the antiviral properties of CAR T cells. She has identified specific immune dysfunction signatures useful for designing innovative immunotherapeutic approaches and is currently conducting a double-blind interventional clinical trial to evaluate the role of the gut microbiota in post-bone marrow transplant immune reconstitution.

She has extensive experience working in BSL-3 and BSL-4 laboratories. Finally, she has obtained multiple competitive research grants, successfully managed numerous scientific projects, and is the author of more than 216 peer-reviewed publications indexed in PubMed and ISI Web of Knowledge. Her h-index is 43 (Scopus, July 2026).

FINANZIAMENTI

- 2025 Project entitled “Antiviral immune profiling in patients with T-ALL treated with CD7 CAR-T Cells to develop new combined immunotherapies” funded by Associazione Italiana Ricerca contro il cancro (AIRC).
Role: Principal Investigator. Grant: 427.000,00 euro
- 2024 Project PNRR (PNRR-MCNT2-2023-12377304) entitled “Impact of postbiotic administration on the immune-reconstitution and clinical outcome of bone marrow transplantation: a double-blind randomized interventional study” funded by Italian Ministry of health
Role: Principal Investigator. Grant: 1.000.000,00 euro
- 2023 Project Hub Life Science – Terapia Avanzata (LSH-TA) PNC-E3-2022-23683269 funded by Italian Ministry of health
Role: Collaborator
- 2020 Multicentric Project entitled “VAX4FRAIL study National Project on Vaccines, COVID and frail patients. A multicentric observational prospective study to assess the immune response of COVID-19 vaccination in frail patients” funded by Italian Ministry of health
Role: Principal Investigator. Grant: 1.173.000,00 euro
- 2020 Project COVID-19 COVID-2020-12371735 entitled “The double-edged role of innate immunity in SARS-CoV-2 infection: Dissecting new potential therapeutic targets”, funded by Italian Ministry of health
Role: Principal Investigator of UO. Grant: 81.131,11 euro
- 2018 Project “EXO-DAA” funded by Regione Lazio
Role: Principal Investigator. Grant: 146.000,00 euro
- 2018 Project European Union's Horizon 2020 nell'ambito delle azioni Marie Skłodowska-Curie. “BE a citizEn Scientist”
Role: Collaborator
- 2016 Project European Union's Horizon 2020: “European HIV Alliance (EHVA)”
Role: Collaborator

- 2010 Ricerca Finalizzata (RF-2010 – 2310899, UO 2) dal titolo “Campylobacter, L. monocytogenes ed E. coli produttori di Verocitotossine (VTEC) in Italia: un approccio di epidemiologia molecolare per identificare le fonti di infezione e i fattori di rischio per l'esposizione umana” finanziato dal Ministero della Salute
Role: Responsible of UO. Grant: 39.550,00 Euro
- 2003 Ricerca Finalizzata (UO 7) dal titolo “Alterazioni linfomonocitarie indotte dal SARS coronavirus) in seno al progetto Aspetti diagnostici, patogenetici ed epidemiologici delle infezioni virali del tratto respiratorio” finanziato dal Ministero della Salute
Role: Responsible of UO
- 2003 Ricerca Finalizzata (RF03.120, UO 3) dal titolo “Interazione immunità naturale-specifica nell'infezione da HCV: ricerca di nuovi bersagli terapeutici” finanziato dal Ministero della Salute
Role: Responsible of UO. Grant 29.100,00 euro

PATENT

- 2012 Patent: “Metodo in vitro per la coltivazione di virus epatitici per effettuare una valutazione rapida dell'efficacia della terapia antivirale”. A nome dell'Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”- I.R.C.C.S e di Innate Pharma. Inventors: Chiara Agrati, Cecile Bonnafous et al.
Filed 15/08/2012 con n. IT2011RM0006620110214. European Extension 08/08/08 con n. WO2009037723.
- 2003 Sviluppo di un brevetto dal titolo: “Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti T antigene specifici” - Inventors: Poccia Fabrizio, Gioia Cristiana, Agrati Chiara, Montesano Carla, Amicosante Massimo, Casetti Rita, D'Offizi Gianpiero, Horejsh Douglas, Martini Federico, Capobianchi Maria Rosaria, Pucillo Leopoldo Paolo, Perrone Donnorso Raffaele, Ippolito Giuseppe.
Filed 05/08/2003 a nome di INMI “Lazzaro Spallanzani” - IRCCS con n. RM2003A000386. European Extension il 05/08/04 con n. PTC/EP2004051726.

LINGUE STRANIERE

	Comprensione		Parlato		Scritto
	Ascolto	Lettura	Interazione Orale	Produzione Orale	
Inglese	C2	C2	C1	C2	C2
Francese	B1	B1	B1	B1	B1

ALTRE ATTIVITA' SCIENTIFICHE

- Attività di Revisore** She serves as a reviewer in the field of immunology for international scientific journals, including Nature Communications, eBioMedicine, Scientific Reports, Journal of Virology, Frontiers in Immunology, Clinical Infectious Diseases, The Journal of Infectious Diseases, and others.\
- Attività di Editore** Member of the Editorial Board of Scientific Reports, Cell Death & Discovery, and Frontiers in Immunology.

**Partecipazione a
Congressi come
Relatrice**

- 2025 Invited speaker at the conference "Bridging the gap: aprocci vaccinali per la popolazione a rischio e immunocompromessa" (Roma, 18/11/2025). Title: Signatures immunologiche di protezione ai vaccini: definire chi, come e quando.
- 2025 Invited speaker at the conference "Le Terapie avanzate per una medicina personalizzata e sostenibile" (Milano, 13/10/2025). Title: Il monitoraggio funzionale delle cellule T specifiche in pazienti sottoposti a trapianto di cellule staminali o immunoterapia.
- 2025 Selected speaker "XV national congresso of SIICA" (Perugia, 17-20/06/2025). Title: Impairment of innate immunity and depletion of vaccine-induced T cells in the absence of the spleen.
- 2025 Invited speaker at the conference "Let's stop HIV" (Venezia, 03-04/12/2025). Title: Immunoterapia avanzata: il ruolo delle cellule CAR-T.
- 2025 Invited speaker at the conference "43 conferenza nazionale di citometria" (Napoli, 26-29/05/2025). Title: Ruolo della milza nell'immunità antivirale.
- 2024 Invited speaker at the conference 16° convegno "Italian Conference on AIDS and Antiviral Research (Roma, 19-21/06/2024)". Title: COVID-19 tie break: a hard shift for immunocompromised patients.
- 2024 Invited speaker at the conference "XXIII Congresso Nazionale SIMIT " (Napoli, 02-05/12/2024). Title: Prevenzione vaccinale nell'adulto: nuove soluzioni per RSV.
- 2024 Invited speaker at the conference "52° Congresso Nazionale della Società Italiana di Microbiologia" (Pavia, 08-11/09/2024). Title: Effective antiviral immunity: a balance between protective and pathogenetic mechanisms.
- 2024 Selected speaker "European Congress of Immunology" (Dublin, 01-04/09/2024). Title: Antiviral protective signature of V δ 2 T cells in pediatric patients after $\alpha\beta$ /CD19-depleted hematopoietic stem cell transplantation.
- 2023 Invited speaker at the conference "Advances in flow cytometry: from research to the clinic for personalized medicine" (Roma, 02/03/2023)- Title: The immune response to SARS-CoV2 mRNA vaccine: correlates of protection and open issues.
- 2023 Invited speaker at the conference "18th International Congress of Immunology" (Cape Town, South Africa, 27/11-02/12/ 2023). Title: SARS-CoV 2 vaccine in immunocompromised children: identification of immune frailties.
- 2023 Invited speaker at the conference "41 conferenza nazionale di citometria" (Napoli, 17-19/05/2022). Title: Studio della risposta immunitaria al vaccino SARS-CoV2: ruolo della citometria a flusso.
- 2022 Invited speaker at the conference "XXI Congresso Nazionale SIMIT " (Roma, 20-23/11/2022). Title: L'immunità cellulo-mediata come correlato di protezione nella vaccinazione anti-SARS-CoV-2.

- 2022 Invited speaker at the conference "Let's stop HIV" (Padova, 15-16/12/2022). Title: Il COVID-19 come paradigma della risposta infiammatoria.
- 2021 Invited speaker at the conference "XXXIX congresso della Società Italiana di Citometria" (Napoli, Italia. 14-18/06/2021). Title: Cellule soppressorie di derivazione mieloide nell'infezione da SARS-CoV-2: ruolo nella patogenesi.
- 2020 Speaker webseminars "I Giovedì della citometria" (17/12/2020). Title: Il bilanciamento della risposta immune in COVID-19: possibile impatto sulla protezione.
- 2019 Invited speaker at the conference "La Citometria a flusso: nuove applicazioni e prospettive future" organizzato dall'ISS (24/10/2019). Title: Infezioni emergenti e citometria a flusso: una sfida sempre nuova.
- 2019 Invited speaker at the conference 11° convegno "Italian Conference on AIDS and Antiviral Research (Milano, Italia, 05-07/06/2019)". Title: New cells in HIV persistence and immune control.
- 2018 Invited speaker at the conference XLVII CONGRESSO NAZIONALE AMCLI (Rimini, Italia. 10-13/11/2018). Title: Come monitorare la risposta immunologica post-trapianto alle infezioni.
- 2017 Selected Speaker at the conference "First International Conference on Zika Virus" (Washington DC, USA. 22-25/02/2017). Abstract selezionato per presentazione orale. Title: "T-cell phenotype and function during human acute ZIKV infection".
- 2016 Selected Speaker at the conference 26th ECCMID (09-12/04/2016) (Amsterdam, Netherlands). Titolo relazione: "Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection".

Conference organization

- 2025 Member of the Organizing Secretariat of the GIC 2025 Congress
- 2017- oggi Member of the Organizing Secretariat of the Annual Congress ICAR

Scientific Societies

- 2001 Member of the National Order of Biologists (registration number: 050846 since 30 May 2001)
- 2025 Member of the Italian Society of Immunology, Clinical Immunology and Allergology SIICA).
- 2020 Member of the Società Italiana di Citometria (dal 2026 eletta nel direttivo)

PREMI

- 2024 Winner of the Michele Leonardo Lo Tufo Award in the "People" category.
Award motivation: recognition of her commitment to scientific research in the field of Immunology.

PUBBLICAZIONI

Fonte Scopus **h-index: 43**
(febbraio 2026) Numero totale di pubblicazioni su riviste internazionali: 216
Numero complessivo di citazioni: 6656
Pubblicazioni **Primo nome:** 33
Pubblicazioni **Ultimo nome:** 32

1. Camici M, Piano Mortari E, Del Duca G, Cimini E, Mazzotta V, De Ponte C, Mastrorosa I, Mazzotta S, Pinnetti C, Notari S, Veronica V, Gili S, Prencipe G, Maggi F, Carsetti R, Girardi E, Antinori A, **Agrati C**. Intravenous immunoglobulin-induced remission of Long COVID: a case report on clinical recovery and immunological mechanisms. Accepted for publication in Lancet Infectious Disease.
2. Grassi G, Gili S, Casetti R, Percario ZA, Tumino N, Vacca P, Lamsira HK, Nardacci R, Notari S, Bordoni V, Cimini E, Cristofanelli F, Rubino D, Nonini F, Affabris E, Marchioni L, **Agrati C**, Sacchi A. Sars-Cov-2 spike protein and plasma from COVID-19 patients induce extracellular traps by myeloid-derived suppressor cells. Front Cell Infect Microbiol. 2025 Nov 13;15:1612198. doi: 10.3389/fcimb.2025.1612198. eCollection 2025. PMID: 41322987
3. Bordoni V, Guarracino F, Lorusso A, Merli P, Ippolito G, Locatelli F, **Agrati C**. The antiviral potential of Vγ9Vδ2 T cells: Therapeutic implications for immunocompromised adult and pediatric hosts. Int Rev Cell Mol Biol. 2025;397:153-183. doi: 10.1016/bs.ircmb.2025.03.004. Epub 2025 Mar 20. PMID: 4111090
4. Chiuchiarelli M, Micheli G, Segala FV, Giuliano G, Del Giacomo P, Dusina A, Matteini E, Frondizi F, Gaudino S, Lisi F, Cimini E, Santangelo R, **Agrati C**, Torti C, Cingolani A. Prolonged survival in HIV-associated Progressive Multifocal Leukoencephalopathy treated with Pembrolizumab: a case series on treatment and long-term follow-up. J Neurovirol. 2025 Feb 19. doi: 10.1007/s13365-025-01243-0. Epub 2025 Feb 19. PMID: 39971875
5. Bordoni V, Cinicola BL, Piano Mortari E, Castilletti C, Guarracino F, Albano C, Accordini S, Baban A, Di Sabatino A, Rossi CM, Lenti MV, Zicari AM, Cirelli R, Spada M, Forni GL, Quinti I, Algeri M, Casale M, Perrotta S, Locatelli F, **Agrati C**, Carsetti R. Impairment of Innate Immunity and Depletion of Vaccine-Induced Memory B and T Cells in the Absence of the Spleen. Am J Hematol. 2025 Feb 15. doi: 10.1002/ajh.27634. Online ahead of print. PMID: 39953916
6. Casetti R, Sacchi A, Mazzotta V, Cristofanelli F, Grassi G, Gili S, Cimini E, Notari S, Bordoni V, Mastrorosa I, Giancola ML, Vergori A, Tempestilli M, Vita S, Mariotti D, Rosati S, Lalle E, Meschi S, Colavita F, Garbuglia AR, Girardi E, Nicastri E, Antinori A, **Agrati C**. Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients. Int Immunopharmacol. 2025 Feb 20;148:113934. doi: 10.1016/j.intimp.2024.113934. Epub 2025 Jan 19. PMID: 39832460
7. Mastronuzzi A, Carsetti R, De Ioris MA, **Agrati C**, Del Baldo G, Russo C, Cefalo MG, Merli P, Perno CF, dell'Anna VA, Serra A, Bordoni V, Piano Mortari E, Marcellini V, Albano C, Linardos G, Costabile V, Sinibaldi M, Guercio M, di Cecca S, Quintarelli C, Locatelli F. Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study. Heliyon. 2024 Jul 11;10(14):e34503. doi: 10.1016/j.heliyon.2024.e34503. eCollection 2024 Jul 30. PMID: 39713186 Free PMC article.
8. Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera A, D'Amore ML, Di Cecca S, Sinibaldi M, Guercio M, Aurigemma M, De Falco P, Fustaino V, Rota R, Pomella S, Cassandri M, Di Giannatale A, **Agrati C**, Bordoni V, Guarracino F, Massa M, Del Baldo G, Becilli M, Milano GM, Del Bufalo F, Locatelli F, De Angelis B. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an

- osteosarcoma model, reducing response to CAR.GD2 T-cells. *J Hematol Oncol.* 2024 Dec 18;17(1):127. doi: 10.1186/s13045-024-01641-7. PMID: 39695851 Free PMC article.
9. Bordoni V, Guarracino F, Galaverna F, Bertaina V, Li Pira G, Rosichini M, Pitisci A, Matusali G, Maggi F, Velardi E, Merli P, Locatelli F, **Agrati C**. Antiviral potential of V δ 2 T cells in children given TCR $\alpha\beta$ /CD19 cell-depleted HLA-haploidentical HSCT. *Blood Adv.* 2025 Mar 11;9(5):990-1002. doi: 10.1182/bloodadvances.2024013902. PMID: 39626282 Free PMC article.
10. Guerrera G, Sambucci M, Timperi E, Picozza M, Misiti A, Placido R, Corbisiero S, D'Orso S, Termine A, Fabrizio C, Gargano F, Eleuteri S, Marchioni L, Bordoni V, Coppola L, Iannetta M, **Agrati C**, Borsellino G, Battistini L. Identification of an immunological signature of long COVID syndrome. *Front Immunol.* 2025 Jan 8;15:1502937. doi: 10.3389/fimmu.2024.1502937. eCollection 2024. PMID: 39845978 Free PMC article.
11. Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondì A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, **Agrati C**, Girardi E, Vaia F, Maggi F, Antinori A; Mpx Vaccine Lazio Study Group. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. *EClinicalMedicine.* 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb.
12. Grassi G, Notari S, Cicalini S, Casetti R, Cimini E, Bordoni V, Gagliardini R, Mazzotta V, Antinori A, **Agrati C**, Sacchi A. In cART-Treated HIV-Infected Patients, Immunologic Failure Is Associated With a High Myeloid-Derived Suppressor Cell Frequency. *J Acquir Immune Defic Syndr.* 2024 Feb 1;95(2):185-189.
13. Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, Mazzotta V, Colavita F, Fusto M, Cimini E, Notari S, D'Aquila V, Lanini S, Lapa D, Gagliardini R, Mariotti D, Giannico G, Girardi E, Vaia F, **Agrati C**, Maggi F, Antinori A. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV. *Vaccines (Basel).* 2023 Nov 22;11(12):1739. doi: 10.3390/vaccines11121739.
14. Picchianti-Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, **Agrati C**, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti F, Spinelli FR, Corpolongo A, Chimenti MS, Ferraioli M, Sebastiani GD, Benucci M, Li Gobbi F, Santoro AP, Capri A, Puro V, Nicastri E, Goletti D. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine. *Vaccines (Basel).* 2023 Nov 2;11(11):1684. doi: 10.3390/vaccines11111684.
15. Biava M, Notari S, Grassi G, Bordini L, Tartaglia E, **Agrati C**, Cimini E, Sberna G, Nicastri E, Antinori A, Girardi E, Vaia F, Maggi F, Lalle E. In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection. *Microorganisms.* 2023 Nov 16;11(11):2787. doi: 10.3390/microorganisms11112787.
16. Pinnetti C, Cimini E, Mazzotta V, Matusali G, Vergori A, Mondì A, Rueca M, Batzella S, Tartaglia E, Bettini A, Notari S, Rubino M, Tempestilli M, Pareo C, Falasca L, Del Nonno F, Scarabello A, Camici M, Gagliardini R, Girardi E, Vaia F, Maggi F, **Agrati C**, Antinori A. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications. *Lancet Infect Dis.* 2024 Feb;24(2):e127-e135.
17. Piano Mortari E, Pulvirenti F, Marcellini V, Terreri S, Salinas AF, Ferrari S, Di Napoli G, Guadagnolo D, Sculco E, Albano C, Guercio M, Di Cecca S, Milito C, Garzi G, Pesce AM, Bonanni L, Sinibaldi M, Bordoni V, Di Cecilia S, Accordini S, Castilletti C, **Agrati C**, Quintarelli C, Zaffina S, Locatelli F, Carsetti R, Quinti I. Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters. *Front Immunol.* 2023 May 25;14:1194225. doi: 10.3389/fimmu.2023.1194225. eCollection 2023.
18. Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S, Lapa D, Haggiag S,

- Prosperini L, Cuzzi G, Salmi A, Quartuccio ME, Altera AMG, Garbuglia AR, Ascoli Bartoli T, Galgani S, Notari S, **Agrati C**, Puro V, Nicastrì E, Gasperini C, Goletti D. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose. *Int J Mol Sci.* 2023 May 10;24(10):8525. doi: 10.3390/ijms24108525.
19. Santoro A, Capri A, Petrone D, Colavita F, Meschi S, Matusali G, Mizzoni K, Notari S, **Agrati C**, Goletti D, Pezzotti P, Puro V. SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel. *Biomedicines.* 2023 Apr 23;11(5):1247. doi: 10.3390/biomedicines11051247.
 20. **Agrati C**, Bartolini B, Bordoni V, Locatelli F, Capobianchi MR, Di Caro A, Castilletti C, Ippolito G. Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. *Front Immunol.* 2023 Mar 9;14:1147871. doi: 10.3389/fimmu.2023.1147871. eCollection 2023.
 21. Mastroianni I, Gagliardini R, Segala FV, Mondì A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastrì E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; **ESCAPE study group**. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). *EClinicalMedicine.* 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar.
 22. Montalbano M, Piccolo P, Lionetti R, Visco-Comandini U, **Agrati C**, Grassi G, Meschi S, Matusali G, Conte F, Angelone F, Ettore GM, Guglielmo N, Maggi F, Francalancia M, Mereu T, Puro V, Girardi E, D'Offizi G. Third dose of SARS-CoV2 mRNA vaccination produces robust persistent cellular and humoral immune responses in liver transplant recipients. *Liver Int.* 2023 May;43(5):1120-1125. doi: 10.1111/liv.15557. Epub 2023 Apr 1.
 23. Bordoni V, Casale M, Pinto VM, Carsetti R, Gianesin B, Gamberini MR, Mazdai L, Barella S, Denotti AR, Colavita F, Perrotta S, Maggio A, Pitrolo L, Quintino S, Caminati M, Mazzi F, Ceolan J, De Franceschi L, Forni GL, Locatelli F, **Agrati C**. Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients. *Am J Hematol.* 2023 Jun;98(6):E145-E147. doi: 10.1002/ajh.26905. Epub 2023 Mar 15.
 24. Rescigno M, **Agrati C**, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. *Front Immunol.* 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124.
 25. D'arminio Monforte A, Tavelli A, Sala M, Mondì A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A; **ICONA Foundation Study Group**. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. *J Antimicrob Chemother.* 2023 Apr 3;78(4):933-945. doi: 10.1093/jac/dkad026.
 26. Rosichini M, Bordoni V, Silvestris DA, Mariotti D, Matusali G, Cardinale A, Zambruno G, Condorelli AG, Flamini S, Genah S, Catanoso M, Del Nonno F, Trezzi M, Galletti L, De Stefanis C, Cicolani N, Petrini S, Quintarelli C, **Agrati C**, Locatelli F, Velardi E. SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity. *J Allergy Clin Immunol.* 2023 Apr;151(4):911-921. doi: 10.1016/j.jaci.2023.01.022. Epub 2023 Feb 8.
 27. Corradini P, **Agrati C**, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study. *Clin Infect Dis.* 2022 May 24:ciac404.
 28. Cinicola BL, Piano Mortari E, Zicari AM, **Agrati C**, Bordoni V, Albano C, Fedele G, Schiavoni

- I, Leone P, Fiore S, Capponi M, Conti MG, Petrarca L, Stefanelli P, Spalice A, Midulla F, Palamara AT, Quinti I, Locatelli F, Carsetti R. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. *Front Immunol.* 2022 Dec 15;13:1094727. doi: 10.3389/fimmu.2022.1094727.
29. Aiello A, Coppola A, Ruggieri S, Farroni C, Altera AMG, Salmi A, Vanini V, Cuzzi G, Petrone L, Meschi S, Lapa D, Bettini A, Haggiag S, Prosperini L, Galgani S, Quartuccio ME, Bevilacqua N, Garbuglia AR, **Agrati C**, Puro V, Tortorella C, Gasperini C, Nicastrì E, Goletti D. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. *J Neurol Neurosurg Psychiatry.* 2022 Dec 15;jnnp-2022-330175. doi: 10.1136/jnnp-2022-330175.
30. **Agrati C**, Cossarizza A, Mazzotta V, Grassi G, Casetti R, De Biasi S, Pinnetti C, Gili S, Mondì A, Cristofanelli F, Lo Tartaro D, Notari S, Maffongelli G, Gagliardini R, Gibellini L, Aguglia C, Lanini S, D'Abramo A, Matusali G, Fontana C, Nicastrì E, Maggi F, Girardi E, Vaia F, Antinori A. Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study. *Lancet Infect Dis.* 2022 Nov 7:S1473-3099(22)00662-4. doi: 10.1016/S1473-3099(22)00662-4.
31. Ciccocanti F, Antonoli M, Sacchi A, Notari S, Farina A, Beccacece A, Fusto M, Vergori A, D'Offizi G, Taglietti F, Antinori A, Nicastrì E, Marchioni L, Palmieri F, Ippolito G, Piacentini M, **Agrati C**, Fimia GM. Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation. *Clin Proteomics.* 2022 Nov 8;19(1):38. doi: 10.1186/s12014-022-09377-7.
32. Di Cosimo S, Lupo-Stanghellini MT, Costantini M, Mantegazza R, Ciceri F, Salvarani C, Zinzani PL, Mantovani A, Ciliberto G, Uccelli A, Baldanti F, Apolone G, Delcuratolo S, Morrone A, Locatelli F, **Agrati C**, Silvestris N. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study. *Front Oncol.* 2022 Oct 20;12:1002168. doi: 10.3389/fonc.2022.1002168. eCollection 2022.
33. Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, **Agrati C**, Garbuglia AR, Meschi S, Lapa D, Cuzzi G, Petrone L, Vanini V, Salmi A, Altera AMG, Repele F, Grassi G, Bettini A, Vita S, Mariano A, Damiani A, Infantino M, Grossi V, Manfredi M, Niccoli L, Puro V, Rosa RD, Salemi S, Sesti G, Scolieri P, Bruzzese V, Benucci M, Cantini F, Nicastrì E, Goletti D. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. *Int J Infect Dis.* 2022 Dec;125:195-208. doi: 10.1016/j.ijid.2022.10.035. Epub 2022 Nov 1.
34. Pulvirenti F, Mortari EP, Putotto C, Terreri S, Fernandez Salinas A, Cinicola BL, Cimini E, Di Napoli G, Sculco E, Milito C, Versacci P, **Agrati C**, Marino B, Carsetti R, Quinti I. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS. *J Allergy Clin Immunol Pract.* 2023 Jan;11(1):292-305.e2. doi: 10.1016/j.jaip.2022.10.010. Epub 2022 Oct 21.
35. **Agrati C**, Castillette C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordini L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastrì E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. *NPJ Vaccines.* 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8.
36. Bordoni V, Mariotti D, Matusali G, Colavita F, Cimini E, Ippolito G, **Agrati C**. SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production. *Cells.* 2022 Sep 17;11(18):2912. doi: 10.3390/cells11182912
37. Cimini E, **Agrati C**. $\gamma\delta$ T Cells in Emerging Viral Infection: An Overview. *Viruses.* 2022 May 27;14(6):1166. doi: 10.3390/v14061166. PMID: 35746638 Free PMC article. Review. (Quartile Q2).

38. D'Abramo A, Vita S, Maffongelli G, Beccacece A, **Agrati C**, Cimini E, Colavita F, Giancola ML, Cavasio A, Nicastrì E; Spallanzani COVID-19 Case Investigation Team. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-CoV-2 Infection: Defining a Treatment Pathway. *Front Immunol.* 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339. eCollection 2022. (Quartile Q1).
39. Pinnetti C, Cimini E, Vergori A, Mazzotta V, Grassi G, Mondì A, Forbici F, Amendola A, Grisetti S, Baldini F, Candela C, Casetti R, Campioni P, Capobianchi MR, **Agrati C**, Antinori A. Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. *Viruses.* 2022 May 5;14(5):970. doi: 10.3390/v14050970. (Quartile Q2).
40. Corradini P, **Agrati C**, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study. *Clin Infect Dis.* 2022 May 24:ciac404. doi: 10.1093/cid/ciac404. Online ahead of print. (Quartile Q1).
41. Grassi G, Notari S, Gili S, Bordoni V, Casetti R, Cimini E, Tartaglia E, Mariotti D, **Agrati C**, Sacchi A. Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good. *Front Immunol.* 2022 Apr 27;13:842949. doi: 10.3389/fimmu.2022.842949. eCollection 2022. (Quartile Q1).
42. Mazzotta V, Cozzi-Lepri A, Colavita F, Lanini S, Rosati S, Lalle E, Mastrorosa I, Cimaglia C, Vergori A, Bevilacqua N, Lapa D, Mariano A, Bettini A, **Agrati C**, Piselli P, Girardi E, Castilletti C, Garbuglia AR, Vaia F, Nicastrì E, Antinori A. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19. *Front Immunol.* 2022 Apr 20;13:868020. doi: 10.3389/fimmu.2022.868020. eCollection 2022. (Quartile Q1).
43. **Agrati C**, Castilletti C, Goletti D, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, Puro V; INMI COVID-19 Vaccine Study Group. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. *Sci Rep.* 2022 Apr 23;12(1):6687. doi: 10.1038/s41598-022-07741-z. PMID: 35461335 Free PMC article.
44. Mondì A, Pinnetti C, Lorenzini P, Plazzi MM, Abbate I, Camici M, **Agrati C**, Grilli E, Gili F, Esvan R, Orchi N, Rozera G, Amendola A, Forbici F, Gori C, Gagliardini R, Bellagamba R, Ammassari A, Cicalini S, Capobianchi MR, Antinori A. Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. *Pharmaceuticals (Basel).* 2022 Mar 26;15(4):403. doi: 10.3390/ph15040403. PMID: 35455400 Free PMC article.
45. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, Cozzi Lepri A, Gallì P, Pinnetti C, Gagliardini R, Mazzotta V, Mastrorosa I, Grisetti S, Colavita F, Cimini E, Grilli E, Bellagamba R, Lapa D, Sacchi A, Marani A, Cerini C, Candela C, Fusto M, Puro V, Castilletti C, **Agrati C**, Girardi E, Vaia F; HIV-VAC Study Group. Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count. *Clin Infect Dis.* 2022 Apr 2:ciac238. doi: 10.1093/cid/ciac238. Online ahead of print. PMID: 35366316 Free PMC article.
46. Gagliardini R, Vergori A, Lorenzini P, Cicalini S, Pinnetti C, Mazzotta V, Mondì A, Mastrorosa I, Camici M, Lanini S, Fusto M, Paulicelli J, Plazzi MM, Marchioni L, **Agrati C**, Garbuglia AR, Piselli P, Nicastrì E, Taglietti F, Palmieri F, D'Offizi G, Girardi E, Vaia F, Antinori A. Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH. *J Clin Med.* 2022 Mar 11;11(6):1546. doi: 10.3390/jcm11061546. PMID: 35329872 Free PMC article.
47. Farroni C, Picchianti-Diamanti A, Aiello A, Nicastrì E, Laganà B, **Agrati C**, Castilletti C, Meschi S, Colavita F, Cuzzi G, Casetti R, Grassi G, Petrone L, Vanini V, Salmi A, Repele F, Altera

- AMG, Maffongelli G, Corpolongo A, Salemi S, Di Rosa R, Nalli G, Sesti G, Vaia F, Puro V, Goletti D. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. *Front Immunol*. 2022 Feb 28;13:846753. doi: 10.3389/fimmu.2022.846753.
48. Terreri S, Piano Mortari E, Vinci MR, Russo C, Alteri C, Albano C, Colavita F, Gramigna G, **Agrati C**, Linardos G, Coltella L, Colagrossi L, Deriu G, Ciofi Degli Atti M, Rizzo C, Scarsella M, Brugaletta R, Camisa V, Santoro A, Roscilli G, Pavoni E, Muzi A, Magnavita N, Scutari R, Villani A, Raponi M, Locatelli F, Perno CF, Zaffina S, Carsetti R. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. *Cell Host Microbe*. 2022 Mar 9;30(3):400-408.e4. doi: 10.1016/j.chom.2022.01.003.
 49. Bordoni V, Matusali G, Mariotti D, Antonioli M, Cimini E, Sacchi A, Tartaglia E, Casetti R, Grassi G, Notari S, Castillette C, Fimia GM, Capobianchi MR, Ippolito G, **Agrati C**. The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals. *iScience*. 2022 Feb 18;25(2):103854. doi: 10.1016/j.isci.2022.103854.
 50. Cimini E, Grassi G, Beccacece A, Casetti R, Castillette C, Capobianchi MR, Nicastri E, **Agrati C**. In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFN γ Production by Circulating V α 2 T Cells. *Viruses*. 2022 Jan 12;14(1):130. doi: 10.3390/v14010130.
 51. Matusali G, Trionfetti F, Bordoni V, Nardacci R, Falasca L, Colombo D, Terri M, Montaldo C, Castillette C, Mariotti D, Del Nonno F, Capobianchi MR, **Agrati C**, Tripodi M, Strippoli R. Pleural Mesothelial Cells Modulate the Inflammatory/Profibrotic Response During SARS-CoV-2 Infection. *Front Mol Biosci*. 2021 Nov 26;8:752616. doi: 10.3389/fmolb.2021.752616.
 52. Montaldo C, Messina F, Abbate I, Antonioli M, Bordoni V, Aiello A, Ciccocanti F, Colavita F, Farroni C, Najafi Fard S, Giombini E, Goletti D, Matusali G, Rozera G, Rueca M, Sacchi A, Piacentini M, **Agrati C**, Fimia GM, Capobianchi MR, Lauria FN, Ippolito G. Multi-omics approach to COVID-19: a domain-based literature review. *J Transl Med*. 2021 Dec 7;19(1):501. doi: 10.1186/s12967-021-03168-8.
 53. Tortorella C, Aiello A, Gasperini C, **Agrati C**, Castillette C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C, Cuzzi G, Cimini E, Tartaglia E, Vanini V, Prosperini L, Haggiag S, Galgani S, Quartuccio ME, Salmi A, Repele F, Altera AMG, Cristofanelli F, D'Abramo A, Bevilacqua N, Corpolongo A, Puro V, Vaia F, Capobianchi MR, Ippolito G, Nicastri E, Goletti D; INMI COVID-19 Vaccine Study Group. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. *Neurology*. 2022 Feb 1;98(5):e541-e554. doi: 10.1212/WNL.0000000000013108.
 54. Pagano MT, Peruzzu D, Busani L, Pierdominici M, Ruggieri A, Antinori A, D'Offizi G, Petrosillo N, Palmieri F, Piselli P, Cicalini S, Notari S, Nicastri E, **Agrati C**, Ippolito G, Vaia F, Gagliardi MC, Capobianchi MR, Ortona E; INMI-ISS COVID-19 team. Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers. *Biol Sex Differ*. 2021 Nov 22;12(1):63. doi: 10.1186/s13293-021-00407-x.
 55. **Agrati C**, Capone S, Castillette C, Cimini E, Matusali G, Meschi S, Tartaglia E, Camerini R, Lanini S, Milleri S, Colloca S, Vitelli A, Folgori A. Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCoV19. *NPJ Vaccines*. 2021 Nov 4;6(1):131. doi: 10.1038/s41541-021-00394-5.
 56. D'Offizi G, **Agrati C**, Visco-Comandini U, Castillette C, Puro V, Piccolo P, Montalbano M, Meschi S, Tartaglia E, Sorace C, Leone S, Lapa D, Grassi G, Goletti D, Ippolito G, Vaia F, Ettore GM, Lionetti R. Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. *Liver Int*. 2021 Oct 31. doi: 10.1111/liv.15089. Online ahead of print.
 57. Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, **Agrati C**, Castillette C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Plazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G, Ottou S, Vita S, Vergori A, D'Abramo A,

- Petrecchia A, Montaldo C, Scalise E, Grassi G, Casetti R, Bordoni V, Notari S, Colavita F, Meschi S, Lapa D, Bordi L, Murachelli S, Tambasco T, Grillo A, Masone E, Marchioni E, Bardhi D, Porzio O, Cocca F, Murachelli S, Turrini I, Malescio F, Ziviani L, Lawlor R, Poli F, Martire F, Zamboni D, Mazzaferri F. GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. *Sci Transl Med*. 2021 Oct 26:eabj1996. doi: 10.1126/scitranslmed.abj1996. Online ahead of print.
58. Piano Mortari E, Russo C, Vinci MR, Terreri S, Fernandez Salinas A, Piccioni L, Alteri C, Colagrossi L, Coltella L, Ranno S, Linardos G, Agosta M, Albano C, **Agrati C**, Castilletti C, Meschi S, Romania P, Roscilli G, Pavoni E, Camisa V, Santoro A, Brugaletta R, Magnavita N, Ruggiero A, Cotugno N, Amodio D, Ciofi Degli Atti ML, Giorgio D, Russo N, Salvatori G, Corsetti T, Locatelli F, Perno CF, Zaffina S, Carsetti R. Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. *Cells*. 2021 Sep 26;10(10):2541. doi: 10.3390/cells10102541.
 59. Cusato J, Tempestilli M, Calcagno A, Vergori A, Piselli P, Antonucci M, Avataneo V, Palermi A, Notari S, Antinori A, Di Perri G, **Agrati C**, D'Avolio A. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. *Nutrients*. 2021 Oct 12;13(10):3571. doi: 10.3390/nu13103571.
 60. Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R, Calabretta L, Verderio P, Ljevar S, Serpenti F, Morelli D, Apolone G, Ippolito G, **Agrati C**, Corradini P. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. *Br J Haematol*. 2021 Oct 14. doi: 10.1111/bjh.17877. Online ahead of print.
 61. Mastroi Rosa I, Tempestilli M, Notari S, Lorenzini P, Fabbri G, Grilli E, Bellagamba R, Vergori A, Cicalini S, Ammassari A, **Agrati C**, Antinori A. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. *Eur J Drug Metab Pharmacokinet*. 2021 Oct 8. doi: 10.1007/s13318-021-00725-w. Online ahead of print.
 62. Picchianti-Diamanti A, Aiello A, Laganà B, Agrati C, Castilletti C, Meschi S, Farroni C, Lapa D, Najafi Fard S, Cuzzi G, Cimini E, Grassi G, Vanini V, Di Rosa R, Salemi S, Nalli G, Salmi A, Repele F, Altera AMG, Maffongelli G, Palazzolo C, Vita S, Leone S, Puro V, Capobianchi MR, Ippolito G, Nicastrì E, Goletti D. Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. *Front Immunol*. 2021 Sep 14;12:740249. doi: 10.3389/fimmu.2021.740249. eCollection 2021.
 63. Tempestilli M, D'Avolio A, De Nicolò A, **Agrati C**, Antinori A, Cicalini S. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. *J Antimicrob Chemother*. 2021 Aug 27;dkab319. doi: 10.1093/jac/dkab319. Online ahead of print.
 64. **Agrati C**, Di Cosimo S, Fenoglio D, Apolone G, Ciceri F, Ciliberto G, Baldanti F, Costantini M, Giannarelli D, Ippolito G, Locatelli F, Mantovani A, Morrone A, Tagliavini F, Uccelli A, Zinzani PL, Silvestris N, Rescigno M. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. *Front Immunol*. 2021 Aug 10;12:704110. doi: 10.3389/fimmu.2021.704110. eCollection 2021.
 65. Sacchi A, Grassi G, Notari S, Gili S, Bordoni V, Tartaglia E, Casetti R, Cimini E, Mariotti D, Garotto G, Beccacece A, Marchioni L, Bibas M, Nicastrì E, Ippolito G, **Agrati C**. Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection. *Cells*. 2021 Aug 17;10(8):2111. doi: 10.3390/cells10082111.
 66. **Agrati C**, Sacchi A, Tartaglia E, Vergori A, Gagliardini R, Scarabello A, Bibas M. The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. *Int J Mol Sci*. 2021 Jul 26;22(15):7942. doi: 10.3390/ijms22157942. PMID: 34360707 Free PMC article.
 67. Montaldo C, Terri M, Riccioni V, Battistelli C, Bordoni V, D'Offizi G, Prado MG, Trionfetti F, Vescovo T, Tartaglia E, Strippoli R, **Agrati C**, Tripodi M. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. *J Hepatol*. 2021 Jul 13:S0168-8278(21)01901-2. doi: 10.1016/j.jhep.2021.07.003. Online ahead of print. PMID: 34271004

68. **Agrati C**, Castillette C, Goletti D, Meschi S, Sacchi A, Matusali G, Bordoni V, Petrone L, Lapa D, Notari S, Vanini V, Colavita F, Aiello A, Agresta A, Farroni C, Grassi G, Leone S, Vaia F, Capobianchi MR, Ippolito G, Puro V, On Behalf Of The Inmi Covid-Vaccine Study Group. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. *Microorganisms*. 2021 Jun 16;9(6):1315. doi: 10.3390/microorganisms9061315. PMID: 34208751 Free PMC article.
69. Puro V, Castillette C, **Agrati C**, Goletti D, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R, Colavita F, Meschi S, Matusali G, Lapa D, Najafi Fard S, Aiello A, Farrone C, Galli P, Capobianchi MR, Ippolito G, On Behalf Of The Inmi Covid-Vaccine Study Group. Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. *Vaccines (Basel)*. 2021 Jun 8;9(6):615. doi: 10.3390/vaccines9060615. PMID: 34201065 Free PMC article.
70. Bibas M, Pittalis S, Orchi N, De Carli G, **Agrati C**, Girardi E, Antinori A, Puro V, Ippolito G. Publisher Correction: Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18-40 years old: a possible HIV indicator condition. *Blood Cancer J*. 2021 Jun 2;11(6):105. doi: 10.1038/s41408-021-00501-8. PMID: 34078877 Free PMC article. No abstract available.
71. Ciccocanti F, Corazzari M, Casetti R, Amendola A, Collalto D, Refolo G, Vergori A, Taibi C, D'Offizi G, Antinori A, **Agrati C**, Fimia GM, Ippolito G, Piacentini M, Nardacci R. High Levels of TRIM5α Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. *Cells*. 2021 May 14;10(5):1207. doi: 10.3390/cells10051207
72. Vergori A, Lorenzini P, Cozzi-Lepri A, Donno DR, Gualano G, Nicastri E, Iacomini F, Marchioni L, Campioni P, Schininà V, Cicalini S, **Agrati C**, Capobianchi MR, Girardi E, Ippolito G, Vaia F, Petrosillo N, Antinori A, Taglietti F; ReCOVeRI Study Group. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. *Sci Rep*. 2021 May 31;11(1):11334
73. Peruzzo D, Pagano MT, Pierdominici M, Ruggieri A, Antinori A, D'Offizi G, Petrosillo N, Palmieri F, Piselli P, Boumis E, Notari S, Nicastri E, **Agrati C**, Ippolito G, Gagliardi MC, Capobianchi MR, Ortona E; INMI-ISS COVID-19 Team. Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19. *Front Pharmacol*. 2021 May 13;12:683529.
74. **Agrati C**, Castillette C, Sacchi A, Colavita F, Capobianchi MR, Puro V, Nicastri E, Ippolito G, Bibas M. Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient. *J Cell Mol Med*. 2021 May 25.
75. Bibas M, Pittalis S, Orchi N, De Carli G, **Agrati C**, Girardi E, Antinori A, Puro V, Ippolito G. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18-40 years old: a possible HIV indicator condition. *Blood Cancer J*. 2021 May 16;11(5):91.
76. Tempestilli M, Stazi GV, Maffongelli G, Marini MC, Ascoli Bartoli T, Ippolito G, Nicastri E, Marchioni L, **Agrati C**. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis. *Eur J Clin Pharmacol*. 2021 May 12:1-3.
77. Grassi G, Vanini V, De Santis F, Romagnoli A, Aiello A, Casetti R, Cimini E, Bordoni V, Notari S, Cuzzi G, Mosti S, Gualano G, Palmieri F, Fraziano M, Goletti D, **Agrati C**, Sacchi A. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. *Front Immunol*. 2021 Apr 26;12:594376.
78. Gagliardini R, Cozzi-Lepri A, Mariano A, Taglietti F, Vergori A, Abdeddaim A, Di Gennaro F, Mazzotta V, Amendola A, D'Offizi G, Palmieri F, Marchioni L, Piselli P, **Agrati C**, Nicastri E, Capobianchi MR, Petrosillo N, Ippolito G, Vaia F, Girardi E, Antinori A. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. *Front Pharmacol*. 2021 Apr 22;12:621676.
79. Occhigrossi L, Rossin F, D'Eletto M, Farrace MG, Ciccocanti F, Petrone L, Sacchi A, Nardacci

- R, Falasca L, Del Nonno F, Palucci I, Smirnov E, Barlev N, **Agrati C**, Goletti D, Delogu G, Fimia GM, Piacentini M. Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. *J Immunol*. 2021 May 15;206(10):2420-2429.
80. D'Abramo A, Vita S, Maffongelli G, Mariano A, **Agrati C**, Castilletti C, Goletti D, Ippolito G, Nicastrì E; Spallanzani COVID-19 Case Investigation Team. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. *Int J Infect Dis*. 2021 Jun;107:247-250.
 81. Ciccocanti F, Di Rienzo M, Romagnoli A, Colavita F, Refolo G, Castilletti C, **Agrati C**, Brai A, Manetti F, Botta L, Capobianchi MR, Ippolito G, Piacentini M, Fimia GM. Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection. *Antiviral Res*. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064.
 82. **Agrati C**, Bordoni V, Sacchi A, Petrosillo N, Nicastrì E, Del Nonno F, D'Offizi G, Palmieri F, Marchioni L, Capobianchi MR, Antinori A, Ippolito G, Bibas M. Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options. *Mediterr J Hematol Infect Dis*. 2021 Mar 1;13(1):e2021016. doi: 10.4084/MJHID.2021.016. eCollection 2021.
 83. Mondì A, Lorenzini P, Castilletti C, Gagliardini R, Lalle E, Corpolongo A, Valli MB, Taglietti F, Cicalini S, Loiacono L, Di Gennaro F, D'Offizi G, Palmieri F, Nicastrì E, **Agrati C**, Petrosillo N, Ippolito G, Vaia F, Girardi E, Capobianchi MR, Antinori A; INMI Recovery study group. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital. *Int J Infect Dis*. 2021 Mar 3:S1201-9712(21)00203-4. doi: 10.1016/j.ijid.2021.02.117. Online ahead of print.
 84. Andreano E, Nicastrì E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, Vacca F, Cardamone D, De Santi C, Torres JL, Ozorowski G, Benincasa L, Jang H, Di Genova C, Depau L, Brunetti J, **Agrati C**, Capobianchi MR, Castilletti C, Emiliozzi A, Fabbiani M, Montagnani F, Bracci L, Sautto G, Ross TM, Montomoli E, Temperton N, Ward AB, Sala C, Ippolito G, Rappuoli R. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. *Cell*. 2021 Feb 23:S0092-8674(21)00224-5. doi: 10.1016/j.cell.2021.02.035. Online ahead of print
 85. Bordoni V, Tartaglia E, Sacchi A, Fimia GM, Cimini E, Casetti R, Notari S, Grassi G, Marchioni L, Bibas M, Capobianchi MR, Locatelli F, Maeurer M, Zumla A, Antinori A, Nicastrì E, Ippolito G, **Agrati C**. The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients. *Int J Infect Dis*. 2021 Feb 10;105:49-53. doi: 10.1016/j.ijid.2021.02.019. Online ahead of print.
 86. Colavita F, Lapa D, Carletti F, Lalle E, Messina F, Rueca M, Matusali G, Meschi S, Bordi L, Marsella P, Nicastrì E, Marchioni L, Mariano A, Scorzolini L, Ascoli Bartoli T, Di Caro A, Ippolito G, Capobianchi MR, Castilletti C; INMI COVID-19 Laboratory Team and **INMI COVID-19 Study Group**. Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. *Open Forum Infect Dis*. 2020 Sep 2;7(10):ofaa403. doi: 10.1093/ofid/ofaa403. eCollection 2020 Oct
 87. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, Palomba P, Mirabella M, Cascioli S, Palange P, Cuccaro I, Milito C, Zumla A, Maeurer M, Camisa V, Vinci MR, Santoro A, Cimini E, Marchioni L, Nicastrì E, Palmieri F, **Agrati C**, Ippolito G, Porzio O, Concato C, Onetti Muda A, Raponi M, Quintarelli C, Quinti I, Locatelli F. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. *Front Immunol*. 2020 Dec 16;11:610300. doi: 10.3389/fimmu.2020.610300. eCollection 2020
 88. Lanini S, Montaldo C, Nicastrì E, Vairo F, **Agrati C**, Petrosillo N, Scognamiglio P, Antinori A, Puro V, Di Caro A, De Carli G, Navarra A, Agresta A, Cimaglia C, Palmieri F, D'Offizi G, Marchioni L, Kobinger GP, Maeurer M, Girardi E, Capobianchi MR, Zumla A, Locatelli F, Ippolito G. COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. *PLoS One*. 2020 Dec 28;15(12):e0244129. doi: 10.1371/journal.pone.0244129. eCollection 2020.

89. Frustaci A, Alfarano M, Verardo R, **Agrati C**, Casetti R, Miraldi F, Galea N, Letizia C, Chimenti C. Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. *Eur Heart J*. 2020 Dec 23;ehaa973. doi: 10.1093/eurheartj/ehaa973. Online ahead of print
90. Calò Carducci FI, De Ioris MA, **Agrati C**, Carsetti R, Perrotta D, D'Argenio P, De Benedetti F, Notari S, Rossi P, Campana A. Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. *Front Pediatr*. 2020 Nov 30;8:576912. doi: 10.3389/fped.2020.576912. eCollection 2020
91. Vita S, Di Bari V, Corpolongo A, Goletti D, Espinosa J, Petracca S, Palmieri F, Nicastrì E; **INMI COVID-19 study groups**. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. *Int J Infect Dis*. 2021 Feb;103:607-610. doi: 10.1016/j.ijid.2020.11.188. Epub 2020 Nov 30
92. Oliverio S, Beltran JSO, Occhigrossi L, Bordoni V, **Agrati C**, D'Eletto M, Rossin F, Borelli P, Amarante-Mendes GP, Demidov O, Barlev NA, Piacentini M. Transglutaminase Type 2 is Involved in the Hematopoietic Stem Cells Homeostasis. *Biochemistry (Mosc)*. 2020 Oct;85(10):1159-1168. doi: 10.1134/S0006297920100041
93. Del Nonno F, Frustaci A, Verardo R, Chimenti C, Nicastrì E, Antinori A, Petrosillo N, Lalle E, **Agrati C**, Ippolito G; INMI COVID study group. Virus-Negative Myopericarditis in Human Coronavirus Infection: Report From an Autopsy Series. *Circ Heart Fail*. 2020 Nov 12;13(11):CIRCHEARTFAILURE120007636. doi: 10.1161/CIRCHEARTFAILURE.120007636
94. Antonioli M, Pagni B, Vescovo T, Ellis R, Cosway B, Rollo F, Bordoni V, **Agrati C**, Labus M, Covello R, Benevolo M, Ippolito G, Robinson M, Piacentini M, Lovat P, Fimia GM. HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. *Autophagy*. 2020 Nov 23:1-14. doi: 10.1080/15548627.2020.1847444. Online ahead of print
95. Sacchi A, Grassi G, Bordoni V, Lorenzini P, Cimini E, Casetti R, Tartaglia E, Marchioni L, Petrosillo N, Palmieri F, D'Offizi G, Notari S, Tempestilli M, Capobianchi MR, Nicastrì E, Maeurer M, Zumla A, Locatelli F, Antinori A, Ippolito G, **Agrati C**. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. *Cell Death Dis*. 2020 Oct 27;11(10):921. doi: 10.1038/s41419-020-03125-1.
96. Mondì A, Cimini E, Colavita F, Cicalini S, Pinnetti C, Matusali G, Casetti R, Maeurer M, Vergori A, Mazzotta V, Gagliardini R, De Zottis F, Schininà V, Girardi E, Puro V, Ippolito G, Vaia F, Capobianchi MR, Castilletti C, **Agrati C**, Antinori A. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. *J Med Virol*. 2021 Mar;93(3):1796-1804. doi: 10.1002/jmv.26556. Epub 2020 Oct 8
97. Pinnetti C, Vergori A, **Agrati C**, Castilletti C, Campioni P, Gagliardini R, Mondì A, Notari S, Amendola A, Cicalini S, Baldini F, Capobianchi MR, Antinori A. SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. *Int J Infect Dis*. 2020 Dec;101:38-41. doi: 10.1016/j.ijid.2020.09.040. Epub 2020 Sep 17
98. **Agrati C**, De Biasi S, Fidanza L, Gibellini L, Nasi M, Pinti M, Cossarizza A. The importance of advanced cytometry in defining new immune cell types and functions relevant for the immunopathogenesis of HIV infection. *AIDS*. 2020 Dec 1;34(15):2169-2185. doi: 10.1097/QAD.0000000000002675
99. Bordoni V, Tartaglia E, Refolo G, Sacchi A, Grassi G, Antinori A, Fimia GM, **Agrati C**. Per2 Upregulation in Circulating Hematopoietic Progenitor Cells During Chronic HIV Infection. *Front Cell Infect Microbiol*. 2020 Jul 21;10:362. doi: 10.3389/fcimb.2020.00362. eCollection 2020
100. de Sousa E, Ligeiro D, Lérias JR, Zhang C, **Agrati C**, Osman M, El-Kafrawy SA, Azhar EI, Ippolito G, Wang FS, Zumla A, Maeurer M. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. *Int J Infect Dis*. 2020 Sep;98:454-459. doi: 10.1016/j.ijid.2020.07.016. Epub 2020 Jul 18
101. **Agrati C**, Mazzotta V, Pinnetti C, Biava G, Bibas M. Venous thromboembolism in people living with HIV infection (PWH). *Transl Res*. 2021 Jan;227:89-99. doi: 10.1016/j.trsl.2020.11.001

- 10.1016/j.trsl.2020.07.007. Epub 2020 Jul 18.
102. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, **Agrati C**, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. Immunological and inflammatory profiles in mild and severe cases of COVID-19. *Nat Commun.* 2020 Jul 8;11(1):3410. doi: 10.1038/s41467-020-17240-2
103. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastrì E, D'Avolio A, Ippolito G, **Agrati C**. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. *J Antimicrob Chemother.* 2020 Jul 1:dkaa239. doi: 10.1093/jac/dkaa239. Online ahead of print. PMID: 32607555
104. Messina F, Giombini E, **Agrati C**, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. COVID 19 INMI Network Medicine for IDs Study Group. Version 2. *J Transl Med.* 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w. PMID: 32522207 Free PMC article.
105. Ramalho R, Rao M, Zhang C, **Agrati C**, Ippolito G, Wang FS, Zumla A, Maeurer M. Immunometabolism: new insights and lessons from antigen-directed cellular immune responses. *Semin Immunopathol.* 2020 Jun;42(3):279-313. doi: 10.1007/s00281-020-00798-w. Epub 2020 Jun 9. PMID: 32519148 Free PMC article. Review
106. **Agrati C**, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, Casetti R, Tartaglia E, Lalle E, D'Abramo A, Castilletti C, Marchioni L, Shi Y, Mariano A, Song JW, Zhang JY, Wang FS, Zhang C, Fimia GM, Capobianchi MR, Piacentini M, Antinori A, Nicastrì E, Maeurer M, Zumla A, Ippolito G. Cell Death Differ. 2020 Jun 8:1-12. doi: 10.1038/s41418-020-0572-6. Online ahead of print. Chiara Agrati, Alessandra Sacchi, Veronica Bordoni, Eleonora Cimini, Stefania Notari, Germana Grassi, Rita Casetti, Eleonora Tartaglia, Eleonora Lalle1, Alessandra D'Abramo, Concetta Castilletti, Yufang Shi, Andrea Mariano, Jin-Wen Song, Ji-Yuan Zhang, Fu-Sheng Wang, Chao Zhang, Gian Maria Fimia, Maria R. Capobianchi, Mauro Piacentini, Emanuele Nicastrì, Markus Maeurer, Alimuddin Zumla, and Giuseppe Ippolito. Expansion of myeloid derived suppressor cells in patients with severe Coronavirus Disease (COVID-2019). *Cell Death and Diff.* In press
107. Zumla A, Wang FS, Ippolito G, Petrosillo N, **Agrati C**, Azhar EI, El-Kafrawy SA, Osman M, Zitzvogel L, Locatelli F, Gorman E, O'Kane C, McAuley D, Maeurer M. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies. *Int J Infect Dis.* 2020 May 17.
108. Frustaci A, Scarpa M, Maria da Riolo R, **Agrati C**, Finato N, Verardo R, Grande C, Chimenti C, Nora C, Russo MA, Livi U. Fabry cardiomyopathy: Gb3-induced auto-reactive perimyocarditis requiring heart transplantation. *ESC Heart Fail.* 2020 Apr 29.
109. Veronica Bordoni, Alessandra Sacchi, Eleonora Cimini, Stefania Notari, Germana Grassi, Eleonora Tartaglia, Rita Casetti, Letizia Giancola, Nazario Bevilacqua, Markus Maeurer, Alimuddin Zumla, Franco Locatelli, Fabrizio De Benedetti, Fabrizio Palmieri, Luisa Marchioni, Maria R Capobianchi, Gianpiero D'Offizi, Nicola Petrosillo, Andrea Antinori, Emanuele Nicastrì, Giuseppe Ippolito, **Chiara Agrati**. An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in COVID-19. *Clin Infect Dis.* 2020 May 15;ciaa577. doi: 10.1093/cid/ciaa577.
110. Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, Palazzolo C, Schininà V, Nicastrì E, Petrosillo N, Campioni P, Eskild P, Zumla A, Ippolito G; **COVID 19 INMI Study Group**. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. *Int J Infect Dis.* 2020 Apr;93:192-197.
111. Macchia I, La Sorsa V, Ruspantini I, Sanchez M, Tirelli V, Carollo M, Fedele G, Leone P, Schiavoni G, Buccione C, Rizza P, Nisticò P, Palermo B, Morrone S, Stabile H, Rugghetti A, Nuti M, Zizzari IG, Fionda C, Maggio R, Capuano C, Quintarelli C, Sinibaldi M, **Agrati C**, Casetti R, Rozo Gonzalez A, Iacobone F, Gismondi A, Belardelli F, Biffoni M, Urbani F.

- Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. *J Immunol Res*. 2020 Apr 12;2020:1938704.
112. Bordini V, Brando B, Piselli P, Forini O, Perna FE, Atripaldi U, Carputo S, Garziano F, Trento E, D'Agosto G, Latini A, Colafigli M, Cristaudo A, Sacchi A, Andreoni M, De Carli G, Orchi N, Grelli S, Gatti A, Cerva C, Minutolo A, Potestà M, Di Martino ML, Ortu F, Selva P, Del Pup L, Guarnori I, Lorenzini P, Capuano G, Antinori A, **Agrati C**. Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. *PLoS One*. 2019 Dec 23;14(12):e0225415. doi: 10.1371/journal.pone.0225415. eCollection 2019.
 113. **Agrati C**, Tumino N, Bordini V, Pinnetti C, Sabatini A, Amendola A, Abbate I, Lorenzini P, Mondì A, Casetti R, Cimini E, Grassi G, Antinori A, Sacchi A. Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. *Front Immunol*. 2019 Aug 8;10:1886. doi: 10.3389/fimmu.2019.01886. eCollection 2019.
 114. Nicastrì E, Vairo F, Mencarini P, Battisti A, **Agrati C**, Cimini E, Carrara S, D'Arezzo S, Adone R, Vulcano A, Iannetta M, Capone A, Petrosillo N, Fasanella A, Ippolito G, Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human-animal investigation of epidemiological, clinical, microbiological and ecological factors. Italian Anthrax Team Members. *Euro Surveill*. 2019 Jun;24(24):1800685. doi: 10.2807/1560-7917.ES.2019.24.24.1800685.
 115. Casetti R, Sacchi A, Bordini V, Grassi G, Cimini E, Besi F, Pinnetti C, Mondì A, Antinori A, **Agrati C**. In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced $\gamma\delta$ T-cell activation but failed to restore their polyfunctionality. *Immunology*. 2019 Aug;157(4):322-330. doi: 10.1111/imm.13089. Epub 2019 Jul 8.
 116. Bordini V, Lalle E, Colavita F, Baiocchi A, Nardacci R, Falasca L, Carletti F, Cimini E, Bordini L, Kobinger G, D'Ambrosio V, Natale F, Giancotti A, Manganaro L, Del Nonno F, Zumla A, Liuzzi G, Ippolito G, Capobianchi MR, **Agrati C**, Castilletti C. Rescue of Replication-Competent ZIKV Hidden in Placenta-Derived Mesenchymal Cells Long After the Resolution of the Infection. *Open Forum Infect Dis*. 2019 Oct 9;6(10):ofz342. doi: 10.1093/ofid/ofz342. eCollection 2019 Oct.
 117. Scognamiglio P, Navarra A, Orchi N, De Carli G, Pittalis S, Mastroianni I, Visco Comandini U, **Agrati C**, Antinori A, Puro V, Ippolito G, Girardi E. Unawareness of HCV serostatus among persons newly diagnosed with HIV. *J Infect Public Health*. 2019 Feb 5. pii: S1876-0341(19)30057-7. doi: 10.1016/j.jiph.2019.01.055. [Epub ahead of print] PubMed PMID: 30737128.
 118. Lapa D, **Agrati C**, Scognamiglio P, Cimini E, Capobianchi MR, Garbuglia AR. GB virus type C cross-reactivity in clinical samples with a low hepatitis C virus antibody positive response. *APMIS*. 2019 Feb;127(2):109-111. doi: 10.1111/apm.12921. PubMed PMID: 30698305.
 119. Sacchi A, Tumino N, Grassi G, Casetti R, Cimini E, Bordini V, Ammassari A, Antinori A, **Agrati C**. A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. *PLoS One*. 2018 Aug 30;13(8):e0202920. doi: 10.1371/journal.pone.0202920. eCollection 2018. PubMed PMID: 30161175; PubMed Central PMCID: PMC6117014.
 120. Colavita F, Bordini V, Caglioti C, Biava M, Castilletti C, Bordini L, Quartu S, Iannetta M, Ippolito G, **Agrati C**, Capobianchi MR, Lalle E. ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. *Mediators Inflamm*. 2018 Jun 3;2018:2450540. doi: 10.1155/2018/2450540. eCollection 2018. PubMed PMID: 29967565; PubMed Central PMCID: PMC6008743.
 121. Sacchi A, Tumino N, Sabatini A, Cimini E, Casetti R, Bordini V, Grassi G, **Agrati C**. Myeloid-Derived Suppressor Cells Specifically Suppress IFN- γ Production and Antitumor Cytotoxic Activity of V δ 2 T Cells. *Front Immunol*. 2018 Jun 6;9:1271. doi: 10.3389/fimmu.2018.01271. eCollection 2018. PubMed PMID: 29928279; PubMed Central PMCID: PMC5997821.
 122. Puro V, Fusco FM, Castilletti C, Carletti F, Colavita F, **Agrati C**, Di Caro A, Capobianchi

- MR, Ippolito G. Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of *Macaca tonkeana* in Lazio Region, Italy, 2015. *Zoonoses Public Health*. 2018 Mar 7. doi: 10.1111/zph.12459. [Epub ahead of print] PubMed PMID: 29512303.
123. Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, **Agrati C**. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. *Liver Int*. 2018 Jan 22. doi: 10.1111/liv.13700. [Epub ahead of print] PubMed PMID: 29359389.
 124. Bordoni V, Viola D, Sacchi A, Pinnetti C, Casetti R, Cimini E, Tumino N, Antinori A, Ammassari A, **Agrati C**. IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. *Cytokine*. 2018 Mar;103:34-37. doi: 10.1016/j.cyto.2017.12.033. Epub 2018 Jan 8. PubMed PMID: 29324258.
 125. Tempestilli M, Fabbri G, Mastroianni I, Timelli L, Notari S, Bellagamba R, Libertone R, Lupi F, Zaccarelli M, Antinori A, **Agrati C**, Ammassari A. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. *J Antimicrob Chemother*. 2018 Jan 1;73(1):160-164. doi: 10.1093/jac/dkx348. PubMed PMID:29106584.
 126. Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, Ammassari A, **Agrati C**. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2017 Dec 12;1073:183-190. doi: 10.1016/j.jchromb.2017.12.018. [Epub ahead of print] PubMed PMID: 29276983.
 127. Cimini E, Bordoni V, Sacchi A, Visco-Comandini U, Montalbano M, Taibi C, Casetti R, Lalle E, D'Offizi G, Capobianchi MR, **Agrati C**. Intrahepatic Vγ9Vδ2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication. *Virus Res*. 2018 Jan 2;243:31-35. doi: 10.1016/j.virusres.2017.10.008. Epub 2017 Oct 10. PubMed PMID: 29029951.
 128. Nicastri E, Brucato A, Petrosillo N, Biava G, Uyeki TM, Ippolito G; **INMI's Ebola Team**. Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. *BMC Infect Dis*. 2017 Aug 30;17(1):597. doi: 10.1186/s12879-017-2689-x. PubMed PMID: 28854896; PubMed Central PMCID: PMC5576302.
 129. Cimini E, Castilletti C, Sacchi A, Casetti R, Bordoni V, Romanelli A, Turchi F, Martini F, Tumino N, Nicastri E, Corpolongo A, Di Caro A, Kobinger G, Zumla A, Capobianchi MR, Ippolito G, **Agrati C**. Human Zika infection induces a reduction of IFN-γ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells. *Sci Rep*. 2017 Jul 24;7(1):6313. doi: 10.1038/s41598-017-06536-x. PubMed PMID: 28740159; PubMed Central PMCID: PMC5524759.
 130. Sacchi A, Tumino N, Turchi F, Refolo G, Fimia G, Ciccocanti F, Montalbano M, Lionetti R, Taibi C, D'Offizi G, Casetti R, Bordoni V, Cimini E, Martini F, **Agrati C**. Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. *Clin Immunol*. 2017 Oct;183:82-90. doi: 10.1016/j.clim.2017.07.017. Epub 2017 Jul 20. PubMed PMID: 28736275.
 131. Cimini E, Viola D, Cabeza-Cabrero M, Romanelli A, Tumino N, Sacchi A, Bordoni V, Casetti R, Turchi F, Martini F, Bore JA, Koundouno FR, Duraffour S, Michel J, Holm T, Zekeng EG, Cowley L, Garcia Dorival I, Doerrbecker J, Hetzelt N, Baum JHJ, Portmann J, Wölfel R, Gabriel M, Miranda O, Díaz G, Díaz JE, Fleites YA, Piñeiro CA, Castro CM, Koivogui L, Magassouba N, Diallo B, Ruibal P, Oestereich L, Wozniak DM, Lüdtke A, Becker-Ziaja B, Capobianchi MR, Ippolito G, Carroll MW, Günther S, Di Caro A, Muñoz-Fontela C, **Agrati C**. Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. *PLoS Negl Trop Dis*. 2017 May 30;11(5):e0005645. doi: 10.1371/journal.pntd.0005645. eCollection 2017 May. PubMed PMID: 28558022; PubMed Central PMCID: PMC5472323.
 132. Colavita F, Biava M, Castilletti C, Quartu S, Vairo F, Caglioti C, **Agrati C**, Lalle E, Bordi

- L, Lanini S, Guanti MD, Miccio R, Ippolito G, Capobianchi MR, Di Caro A; Lazzaro Spallanzani Institute for Research and Health Care Ebola Virus Disease Sierra Leone Study Group. Measles Cases during Ebola Outbreak, West Africa, 2013-2106. *Emerg Infect Dis.* 2017 Jun;23(6):1035-1037. doi: 10.3201/eid2306.161682. PubMed PMID: 28518027; PubMed Central PMCID: PMC5443435.
133. Casetti R, Pinnetti C, Sacchi A, De Simone G, Bordoni V, Cimini E, Tumino N, Besi F, Viola D, Turchi F, Mazzotta V, Antinori A, Martini F, Ammassari A, **Agrati C**. HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. *J Acquir Immune Defic Syndr.* 2017 Jul 1;75(3):338-344. doi: 10.1097/QAI.0000000000001392. PubMed PMID: 28418988.
134. Tumino N, Casetti R, Fabbri G, Cimini E, Romanelli A, Turchi F, Forini O, Bordoni V, Antinori A, Ammassari A, Sacchi A, **Agrati C**. In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. *J Hepatol.* 2017 Apr 12. pii: S0168-8278(17)30207-6. doi: 10.1016/j.jhep.2017.03.036. [Epub ahead of print] PubMed PMID: 28411041.
135. Bordoni V, Bibas M, Viola D, Sacchi A, Cimini E, Tumino N, Casetti R, Amendola A, Ammassari A, **Agrati C**, Martini F. Bone Marrow CD34(+) Progenitor Cells from HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines. *AIDS Res Hum Retroviruses.* 2017 Jun;33(6):590-596 doi: 10.1089/AID.2016.0195. Epub 2017 Feb 22. PubMed PMID: 28125903.
136. Tumino N, Bilotta MT, Pinnetti C, Ammassari A, Antinori A, Turchi F, **Agrati C**, Casetti R, Bordoni V, Cimini E, Abbate I, Capobianchi MR, Martini F, Sacchi A. Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. *J Acquir Immune Defic Syndr.* 2017 Apr 15;74(5):575-582. doi: 10.1097/QAI.0000000000001283. PubMed PMID: 28060224.
137. Bordoni V, Sacchi A, Cimini E, Casetti R, Tumino N, Ammassari A, **Agrati C**, Martini F. The Different Roles of Interleukin 7 and Interleukin 18 in Affecting Lymphoid Hematopoietic Progenitor Cells and CD4 Homeostasis in Naive Primary and Chronic HIV-Infected Patients. *Clin Infect Dis.* 2016 Dec 15;63(12):1683-1684. [IF 8.88]
138. Nicastri E, Balestra P, Ricottini M, Petrosillo N, Di Caro A, Capobianchi MR, Giancola ML, Ippolito G; **INMI's Ebola Team**. Temporary neurocognitive impairment with Ebola virus. *J Neurol Neurosurg Psychiatry.* 2016 Jul 19. pii: jnnp-2016-313695. doi: 10.1136/jnnp-2016-313695. [IF 6.807]
139. **Agrati C**, Castilletti C, Cimini E, Romanelli A, Lapa D, Quartu S, Martini F, Capobianchi MR. Antiviral activity of human Vδ2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. *New Microbiol.* 2016 Apr;39(2):139-42. [IF 1.78]
140. Ruibal P, Oestereich L, Lüdtke A, Becker-Ziaja B, et al. Unique human immune signature of Ebola virus disease in Guinea. *Nature.* 2016 May 5;533(7601):100-4. [IF 41.45]
141. **Agrati C**, Castilletti C, Casetti R, Sacchi A, Falasca L, Turchi F, Tumino N, Bordoni V, Cimini E, Viola D, Lalle E, Bordini L, Lanini S, Martini F, Nicastri E, Petrosillo N, Puro V, Piacentini M, Di Caro A, Kobinger GP, Zumla A, Ippolito G, Capobianchi MR. Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. *Cell Death Dis.* 2016 Mar 31;7:e2164. doi: 10.1038/cddis.2016.55. [IF 5.11]
142. Bevilacqua N, Nicastri E, Chinello P, Puro V, Petrosillo N, Di Caro A, Capobianchi MR, Lanini S, Vairo F, Pletschette M, Zumla A, Ippolito G; **INMI Ebola Team**. Criteria for discharge of patients with Ebola virus diseases in high-income countries. *Lancet Glob Health.* 2015 Dec;3(12):e739-40. PubMed PMID: 26608193. [IF 10.04]
143. Salce L, Barbato S, Renna D, Bianchini F, Vaccaro P, Mazzeo F, Gasparini A, Rizza C, Lanfranchi E, Petrosillo N, Nicastri E, Di Caro A, Capobianchi MR, Puro V, Ippolito G; **INMI EBOV Team**. First Italian Ebola virus disease case: management of hospital internal and external communication. *New Microbiol.* 2015 Oct;38(4):565-70. [IF 1.67]
144. Petrosillo N, Nicastri E, Lanini S, Capobianchi MR, Di Caro A, Antonini M, Puro V, Lauria FN, Shindo N, Magrini N, Kobinger GP, Ippolito G; **INMI EBOV Team**. Ebola virus disease complicated with viral interstitial pneumonia: a case report. *BMC Infect Dis.* 2015 Oct

- 16;15:432. doi: 10.1186/s12879-015-1169-4. [IF 3.11]
145. Tumino N, Turchi F, Meschi S, Lalle E, Bordoni V, Casetti R, **Agrati C**, Cimini E, Montesano C, Colizzi V, Martini F, Sacchi A. In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3 ζ expression through ELF-1 inhibition. *AIDS*. 2015 Nov 28;29(18):2397-407. [IF 6.55]
 146. Casetti R, De Simone G, Sacchi A, Rinaldi A, Viola D, **Agrati C**, Bordoni V, Cimini E, Tumino N, Besi F, Martini F. V γ 9V δ 2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count. *PLoS One*. 2015 Jul 10;10(7):e0132291. [IF 4.35]
 147. Cimini E, **Agrati C**, D'Offizi G, Vlassi C, Casetti R, Sacchi A, Lionetti R, Bordoni V, Tumino N, Scognamiglio P, Martini F. Primary and Chronic HIV Infection Differently Modulates Mucosal V δ 1 and V δ 2 T-Cells Differentiation Profile and Effector Functions. *PLoS One*. 2015 Jun 18;10(6):e0129771. doi: 10.1371/journal.pone.0129771. [IF 4.35]
 148. Tempestilli M, Pucci L, Notari S, Di Caro A, Castilletti C, Rivelli MR, **Agrati C**, Pucillo LP. Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. *Clin Chem Lab Med*. 2015 Nov;53(12):1967-73. [IF 3.00]
 149. Falasca L, **Agrati C**, Petrosillo N, Di Caro A, Capobianchi MR, Ippolito G, Piacentini M. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. *Cell Death Differ*. 2015 Aug;22(8):1250-9. [IF 8.38]
 150. Bordoni V, Bibas M, Abbate I, Viola D, Rozera G, **Agrati C**, Rinaldi A, Amendola A, Ammassari A, Capobianchi MR, Martini F. Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients. *Clin Microbiol Infect*. 2015 Mar;21(3):290.e5-8. [IF 4.54]
 151. Bordoni V, Casetti R, Viola D, Abbate I, Rozera G, Sacchi A, Cimini E, Tumino N, **Agrati C**, Orchi N, Pinnetti C, Ammassari A, Martini F. Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. *J Antimicrob Chemother*. 2015 May;70(5):1598-600. [IF 5.33]
 152. **Agrati C**, Izzo L, Berno G, Cimini E, Bordoni V, Giancola ML, Baldini F, Colasanti M, Ettorre GM, Izzo P, Pugliese F, Angrisani M, Di Cello P, Capobianchi MR, Bolognese A. JCV-specific T-cells producing IFN-gamma are differently associated with PmL occurrence in HIV patients and liver transplant recipients. *New Microbiol*. 2015 Jan;38(1):85-9. [IF 1.78]
 153. Sacchi A, Rinaldi A, Tumino N, Casetti R, **Agrati C**, Turchi F, Bordoni V, Cimini E, Martini F. HIV Infection of Monocytes-Derived Dendritic Cells Inhibits V γ 9V δ 2 T Cells Functions. *PLoS One*. 2014 Oct 23;9(10). [IF 4.35]
 154. Cimini E, Bordoni V, Lalle E, Montalbano M, Visco-Comandini U, Taibi C, D'Offizi G, Lionetti R, Scognamiglio P, Capobianchi MR, Martini F, **Agrati C**. Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system. *New Microbiol*. 2014 Jul;37(3):363-7. [IF 1.78]
 155. **Agrati C**, Castilletti C, Cimini E, Lapa D, Quartu S, Caglioti C, Lanini S, Cattoli G, Martini F, Ippolito G, Capobianchi MR. Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. *PLoS One*. 2014 Aug 27;9(8). [IF 4.35]
 156. Casetti R, De Simone G, Sacchi A, Bordoni V, Viola D, Rinaldi A, **Agrati C**, Gioia C, Martini F. Modulation of polyfunctional HIV-specific CD8 T cells in patients responding differently to antiretroviral therapy. *Int J Immunopathol Pharmacol*. 2014 Apr-Jun;27(2):291-7. [IF 2.99]
 157. Capobianchi MR, Garbuglia AR, **Agrati C**, Rianda A, Noto P, Corpolongo A, Cataldo MA, Rosati S, Zaccaro P, Loffredo M, Pompa MG, Girardi E, Scognamiglio P, Ippolito G; GEAS Group. Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, January-July 2013. *Microbes Infect*. 2014 Apr;16(4):362-6. [IF 2.80]
 158. Baldini F, Baiocchi A, Schininà V, **Agrati C**, Giancola ML, Alba L, Grisetti S, Del Nonno F, Capobianchi MR, Antinori A. Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy. *BMC Infect Dis*. 2013 Dec 21;13:600. [IF 3.11]

159. Bordoni V, Bibas M, Viola D, Sacchi A, **Agrati C**, Castelli G, Ammassari A, Amendola A, Abbate I, Martini F. Chronic HIV-infected patients show an impaired dendritic cells differentiation of bone marrow CD34⁺ cells. *J Acquir Immune Defic Syndr*. 2013 Dec 1;64(4):342-4. [IF 4.56]
160. Bordoni V, Castelli G, Montesoro E, Federico M, Sacchi A, Morsilli O, **Agrati C**, Martini F, Chelucci C. HIV impairs CD34⁺-derived monocytic precursor differentiation into functional dendritic cells. *Int J Immunopathol Pharmacol*. 2013 Jul-Sep;26(3):717-24. [IF 2.99]
161. Cimini E, Bonnafous C, Sicard H, Vlassi C, D'Offizi G, Capobianchi MR, Martini F, **Agrati C**. In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection. *J Interferon Cytokine Res*. 2013 Mar;33(3):136-41. [IF 3.20]
162. Bordoni V, Casetti R, Capuano G, De Stefani B, Piselli P, Gioia C, **Agrati C**, Martini F. A novel 8-color flow cytometry panel to study activation, maturation and senescence of CD4 and CD8 T lymphocytes in HIV-infected individuals at different stages of disease. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2):415-24. [IF 2.99]
163. Cimini E, Bonnafous C, Bordoni V, Lalle E, Sicard H, Sacchi A, Berno G, Gioia C, D'Offizi G, Visco Comandini U, Vlassi C, Capobianchi MR, Martini F, **Agrati C**. Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection. *PLoS One*. 2012;7(5). [IF 4.35]
164. Bordoni V, **Agrati C**, Rinaldi A, Viola D, De Simone G, Gioia C, Martini F. In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by ≥ 7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation. *J Antimicrob Chemother*. 2012 Jul;67(7):1802-4. [IF 5.33]
165. **Agrati C**, Gioia C, Castilletti C, Lapa D, Berno G, Puro V, Carletti F, Cimini E, Nisii C, Castellino F, Martini F, Capobianchi MR. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. *AIDS Res Hum Retroviruses*. 2012 Dec;28(12):1606-16. [IF 2.24]
166. De Paolis P, Favaro A, Piola A, Martini F, Cristiana G, **Agrati C**, Iappelli M, Di Giulio S. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. *Transplant Proc*. 2011 May;43(4):1013-6. [IF 0.99]
167. Cimini E, Piacentini P, Sacchi A, Gioia C, Leone S, Lauro GM, Martini F, **Agrati C**. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines. *Int J Immunopathol Pharmacol*. 2011 Jan-Mar;24(1):139-48. [IF 2.99]
168. **Agrati C**, D'Offizi G, Gougeon ML, Malkovsky M, Sacchi A, Casetti R, Bordoni V, Cimini E, Martini F. Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies? *AIDS Rev*. 2011; 13(1):3-12. [IF 3.51]
169. Sacchi A, **Agrati C**, D'Offizi G, Vlassi C, Rozera G, Abbate I, Capobianchi MR, Martini F. The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. *Clin Immunol*. 2011 Feb;138(2):178-86. [IF 4.04]
170. **Agrati C**, Marianecchi C, Sennato S, Carafa M, Bordoni V, Cimini E, Tempestilli M, Pucillo LP, Turchi F, Martini F, Borioni G, Bordini F. Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. *Nanomedicine*. 2011 Apr;7(2):153-61. [IF 5.05]
171. Sacchi A, **Agrati C**, D'Offizi G, Vlassi C, Martini F. Co-stimulatory molecule CD80 expression may correlate with anti-HCV treatment outcome. *Gut*. 2011;60(8):1161-2. [IF 10.61]
172. **Agrati C**, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O, Lauria FN, Ferraro F, Antonini M, Ippolito G, Capobianchi MR, Martini F. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. *J Infect Dis*. 2010 Sep 1;202(5):681-9. [IF 5.77]
173. Casetti R, **Agrati C**, Wallace M, Sacchi A, Martini F, Martino A, Rinaldi A, Malkovsky M. Cutting edge: TGF-beta1 and IL-15 Induce FOXP3⁺ gamma delta regulatory T cells in the presence of antigen stimulation. *J Immunol*. 2009; 15;183(6):3574-7. [IF 5.52]
174. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, **Agrati C**, Amendola A, Abdeddaim A, Vlassi C, Malkovsky M, D'Offizi G. Zoledronic acid and interleukin-2

- treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. *AIDS*. 2009; Mar 13;23(5):555-65. [IF 6.55]
175. **Agrati C**, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Martini F. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. *J Immunol*. 2009; Jan 1;182(1):522-9. [IF 5.52]
 176. Sacchi A, Tempestilli M, Turchi F, **Agrati C**, Casetti R, Cimini E, Gioia C, Martini F. CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients. *J Infect Dis*. 2009; Feb 1;199(3):432-6. [IF 5.77]
 177. Casetti R, Martino A, Sacchi A, **Agrati C**, Goletti D, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? *Blood*. 2008; 1;112(12):4776-7. [IF 10.55]
 178. Gioia C, **Agrati C**, Castilletti C, Capobianchi MR, Martini F. Influenza pandemics, immune cross-reactivity, and pandemic control strategies. *J Infect Dis*. 2008; Jul 15;198(2):294-5. [IF 5.77]
 179. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, **Agrati C**, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. *Cancer Immunol Immunother*. 2009; Jan;58(1):31-8. [IF 3.79]
 180. Penitente R, Nicolò C, Van den Elzen P, Di Sante G, **Agrati C**, Aloisi F, Sercarz EE, Ria F. Administration of PLP139-151 primes T cells distinct from those spontaneously responsive in vitro to this antigen. *J Immunol*. 2008; May 15;180(10):6611-22. PubMed PMID: 18453580. [IF 5.52]
 181. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, **Agrati C**, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. *Emerg Infect Dis*. 2008 Jan;14(1):121-8. [IF 6.44]
 182. **Agrati C**, Volpi I, Martini F., Gioia C., Castilletti G., Ippolito G., Capobianchi MR., and Poccia F. Rapid and Biologically safe procedure for the evaluation of antigen-specific T cell response to microbial pathogens that may be used in BSL4 environment. *Applied Biosafety* 2008;
 183. **Agrati C**, Gioia C., Soldani F., Martini F., Antinori A., Poccia F. T cell selection and differentiation in AIDS disease: the model of HIV-discordant monozygotic twins. *J Biol Regul Homeost Agents*. 2008; 20(1-2):24-8 [IF: 0.99].
 184. Nisii C, Tempestilli M, **Agrati C**, Poccia F, Tocci G, Longo MA, D'Offizi G, Tersigni R, Lo Iacono O, Antonucci G, Oliva A. Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. *J Hepatol*. 2006; 44(3):475-483. [IF 4.931].
 185. **Agrati C**, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR, D'Offizi G, Siepi F, Fimia GM, Tripodi M, Poccia F. Activation of V{gamma}9V{delta}2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. *Int Immunol*. 2006; 18(1):11-8. [IF: 3.317]
 186. **Agrati C**, Castilletti C, De Santis R, Cimini E, Bordi L, Malkovsky M, Poccia F, Capobianchi MR. Interferon-gamma-mediated antiviral immunity against orthopoxvirus infection is provided by gammadelta T cells. *J. Infect. Dis*. 2006; 193: 1606. [IF: 4.953].
 187. Poccia F., **Agrati C**, Castilletti C., Bordi L., Gioia C., Horejsh D., Ippolito G. Chan PKS, Hui DSC, Sung JJY, Capobianchi M., Malkovsky M. Anti-SARS immunity: the role of Vg9Vd2 T lymphocytes. *J. Infect. Dis*. 2006; 193(9): 1244-9. [IF: 4.953].
 188. Poccia F, **Agrati C**, Martini F, Mejia G, Wallace M, Malkovsky M. Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. *Immunol Lett*..2005; 100(1):14-20. [IF: 2.301].
 189. Martino A, Sacchi A, Volpe E, **Agrati C**, De Santis R, Pucillo LP, Colizzi V, Vendetti S. Non-Pathogenic Mycobacterium smegmatis induces the Differentiation of Human Monocytes directly into fully mature Dendritic Cells. *J. Clin. Immunol*. 2005; 25(4):365-75. [IF: 2.638]
 190. Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, **Agrati C**, Abbate I, Capobianchi MR. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of

- virus replication. *Virology*. 2005; 341(1):163-9. [IF: 3.080]
191. **Agrati C**, Martini F, Nisii C, Oliva A, D'Offizi G, Narciso P, Nardacci R, Piacentini M, Dieli F, Pupillo LP, Poccia F. Preferential CD1d expression by hepatocytes resulting in a main restriction element for intrahepatic T-cell recognition. *J Biol Regul Homeost Agents*. 2005; 19(1-2):41-8. [IF: 0.99].
 192. Martini F, **Agrati C**, D'Offizi G, Poccia F. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. *Int J Immunopathol Pharmacol*. 2005; 18(2):269-76 [IF: 3.418].
 193. Poccia F, **Agrati C**, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gammadelta T cells. *Microbes Infect*. 2005 ;7(3):518-28. [IF: 3.154]
 194. Martini F, Solmone M, **Agrati C**, Capobianchi MR, Iacomì F, Antonucci G, Poccia F. Influence of GB virus type C and HIV coinfection on gamma delta T cells. *Clin Infect Dis*. 2005; 40(2):326-8; [IF: 6.510]
 195. Gioia C, Horejsh D, **Agrati C**, Martini F, Capobianchi MR, Ippolito G and Poccia F. T-cell response profiling to biological threat agents including the SARS Coronavirus. *Int J Immunopathol Pharmacol*. 2005; 1(3):525-30. [IF: 3.418]
 196. Bordoni V, Alonzi T, **Agrati C**, Poccia F, Fimia GM, Piacentini M, Fantoni A and Tripodi M. (2004) "Stem cells differentiation towards NK cells induced by hepatocyte conditioned medium". *Immunology 2004 - International Proceedings Volume* ISBN 88-7587-069- [IF: 3.507]
 197. Bordoni V, Alonzi T, **Agrati C**, Poccia F, Borsellino G, Mancino G, Fimia GM, Piacentini M, Fantoni A, Tripodi M. Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors. *Hepatology*. 2004 Jun;39(6):1508-16. [IF: 9.792]
 198. Alonzi T, **Agrati C**, Costabile B, Cicchini C, Amicone L, Cavallari C, Rocca CD, Folgori A, Fipaldini C, Poccia F, Monica NL, Tripodi M. Steatosis and intrahepatic lymphocyte recruitment in hepatitis C virus transgenic mice. *J Gen Virol*. 2004 Jun;85(Pt 6):1509-20. [IF: 3,013]
 199. Cossarizza A., Poccia F., **Agrati C**., D'Offizi G., Bugarini R., Pinti M., Bedini A., Borghi V., Mussini C., Esposito R., Ippolito G and Narciso P. Highly active antiretroviral therapy restores Vb T cell repertoire in patients with primary HIV infection but only qualitatively in naive HIV+ patients with chronic infection. *J Acquir Immune Defic Syndr*. 2004; 35(3):213-22. [IF: 3,871]
 200. Gioia C., **Agrati C**., Goletti D., Vincenti D., Carrara S., Amicosante M., Casarini M., Giosue S., Puglisi G., Rossi A., Colizzi V., Pucillo L.P., Poccia F. Different cytokine production and effector/memory dynamics of ab or gd T-cell subset in the peripheral blood of patients with active pulmonary tuberculosis. *International Journal of immunopathology and Pharmacology* 2003; 16(3):247-252. [IF: 3.418]
 201. **Agrati C**., Poccia F., Topino S., Narciso P., Selva C., Antonelli G., Bellomi F., Turriziani O., Bambacioni F., Pucillo L.P., and D'Offizi G. P-glycoprotein expression by peripheral mononuclear cells from HIV-infected patients is independent from HAART. *Clin Diagn Lab Immunol* 2003; 10(1):191-192. [IF: 2.056]
 202. G. D'Offizi, C. Montesano, C. **Agrati**, C. Gioia, M. Amicosante, S. Topino, P. Narciso, L. P. Pucillo, G. Ippolito and F. Poccia. Expansion of pre-terminally differentiated CD8+ T-cells in chronic HIV+ patients presenting a rapid viral rebound during STI, *AIDS* 2002; 16:1-8. [IF: 5.835]
 203. Poccia F. and **Agrati C**. Intrahepatic non-specific immunity and HCV immunopathogenesis. *Cell Death Differ*. 2003; 10 Suppl 1:S9-S12. [IF: 7.785]
 204. **Agrati C**, C. Nisii, A. Oliva, G. D'Offizi, C. Montesano, L.P. Pucillo, F. Poccia. Lymphocytes distribution and intrahepatic compartmentalization during HCV infection: a main role of MHC-unrestricted T cells. *Arch Immunol Ther Exp* 2002; 50(5):307-16. [IF: 1.000]
 205. Poccia F., Gougeon M.L., **Agrati C**., Montesano C., Martini F., Pauza C.D., Fisch P., Wallace M., and Malkovsky M. Innate T-cell immunity in HIV infection: The role of Vg9Vd2 T lymphocytes. *Current Molecular Medicine* 2002; 2:485-505. [IF: 4.941]

206. F.Martini, F.Poccia, D.Goletti, S.Carrara, D.Vincenti, G.D'Offizi, C.Agrati, G.Ippolito, L.P.Pucillo, V.Colizzi and C.Montesano. Vg9Vd2 T cell impairments during viral rebound in chronic HIV-infected patients undergoing Structured Treatment Interruption. *J. Inf. Dis.* 2002; 186:847-850. [IF: 4.953]
207. D'Offizi G., Ciapparoni V., Gioia C., Goletti D., **Agrati C.**, Pucillo L.P., Narciso P. and Poccia F. The loss of CMV-specific CD27- T cell effectors in a patient with recurrences of CMV retinitis is independent of HIV-1 viremia. *Infection* 2002; 30:323-325. [IF: 1.854]
208. Gougeon ML, Malkovsky M, Casetti R, **Agrati C**, Poccia F. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? *Vaccine* 2002; 20(15): 1938-41. [IF: 2.822]
209. Gioia C, **Agrati C**, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9 V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. *J Immunol.* 2002; 168(3):1484-9. [IF: 6.387]
210. Montesano C, Gioia C, Martini F, **Agrati C**, Cairo C, Pucillo LP, Colizzi V, and Poccia F. Antiviral activity and anergy of gd T lymphocytes in cord blood and immunocompromised host. *J Biol Regul Homeost Agents.* 2001; 15 (3):257-64. [IF: 0,99]
211. **Agrati C.**, D'Offizi G., Narciso P., Selva C., Pucillo L.P., Ippolito G., Poccia F. gd T cell activation by chronic HIV infection may contribute to intrahepatic Vd1 compartmentalization and HCV-disease progression independently of HAART. *AIDS Research and Human Retrovirus* 2001; 17 (14): 1357-63. [IF: 2.531]
212. Poccia F, **Agrati C**, Ippolito G, Colizzi V and Malkovsky M. Natural T cell immunity to intracellular pathogens and nonpeptidic immunoregulatory drugs. *Current Molecular Medicine* 2001; 1:137-151. [IF: 4.941]
213. **Agrati C**, D'Offizi G, Narciso L, Abrignani S, Ippolito G, Colizzi V, and Poccia F. Vd1+ T Lymphocytes Expressing a Th1 phenotype Are the Major gd T Cell Subset Infiltrating the Liver of HCV-infected Persons. *Molecular Medicine* 2001; 7(1): 11-19. [IF: 3.349]
214. Biagioni S., Tata A.M., **Agrati C.**, Cianfarani F., Augusti-Tocco G. Modulation of cholinergic marker expression by nerve growth factor in dorsal root ganglia. *J. Neurosci. Res.* 2000; 62: 591-599. [IF: 3.239]
215. **Agrati C.**, Poccia F., and Colizzi V. Vaccinazione con antigeni non proteici. IV corso di biologia cellulare e molecolare in pneumologia. *Cuzzolin Editore*, 2000.
216. Tata A.M., Vilarò M.T., **Agrati C.**, Biagioni S., Mengod G., and Augusti-Tocco G. Expression of muscarinic m2 receptor mRNA in dorsal root ganglia of neonatal rat. *Brain Research* 1999; 824: 63-70. [IF: 2.296]

OTHER

Driving Licence Licence A and B

Hobbies Plays piano and guitar; engages in volunteer activities; participates in theater.

Rome, 18 January 2026

Autorizzo il trattamento dei miei dati personali ai sensi del Regolamento UE 2016/679

Roma, 18/01/2026